Episurf Medical reaches milestone of 300 implants
Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of its 300th surgery with the Episealer® implant in the coming weeks.
“Strong clinical results, a growing user group among European surgeons, our 300th implant in production, a significant increase in the interest for the Episealer® technology within the orthopaedic industry, and most importantly, a continuous flow of successful patient outcomes. All of this sums it up, Episurf Medical is continuing to establish the Episealer® technology as a treatment alternative for early knee cartilage and bone damages“ says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09.30 CET on 12 December 2017.